Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation

Highlights

- Nociceptor sensory neuron ablation reduces allergic airway inflammation
- QX-314 enters through large-pore ion channels to silence airway sensory neurons
- IL-5 triggers sensory neuron release of peptides that drive immune cell responses
- Silencing nociceptors is a new strategy to treat type 2 inflammation and allergies

Authors

Sébastien Talbot, Raja-Elie E. Abdulnour, Patrick R. Burkett, ..., Bruce P. Bean, Bruce D. Levy, Clifford J. Woolf

Correspondence

blevy@partners.org (B.D.L.), clifford.woolf@childrens.harvard.edu (C.J.W.)

In Brief

Talbot et al. provide mechanistic insights into how neuro-immune interplay amplifies type 2 allergic airway inflammation. Based on this, they propose a new treatment strategy for asthma, using charged sodium channel blockers to selectively silence sensory neurons in the lung.
Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation


INTRODUCTION

Asthma is an inflammatory airway disease caused by environmental (allergens, air pollution, cold, and smoking) and genetic interactions (Martinez, 2007). The disease affects 7%–10% of the world’s population, causes ~250,000 deaths annually (Akinbami, 2006), and its prevalence is increasing (Ramsey and Celodón, 2005). Asthma symptoms include wheezing, coughing, chest tightness, and shortness of breath, caused by increased airway hyperresponsiveness, inflammation, mucus hypersecretion, and structural remodeling (Locksley, 2010). Histopathology shows goblet cell metaplasia, thickened basement membranes, increased airway smooth muscle, and inflammatory cell infiltration (Locksley, 2010). Immune cells, particularly innate lymphoid cell type 2 (ILC2), helper 2 (Th2) cells, and eosinophils, are central to the pathological airway transformation. Inhaled allergens, such as house dust mites (HDMs), viruses, or bacteria, are sensed mainly by dendritic cells in the lung mucosa, which promote precursor Th cell differentiation into Th2 cells. These, along with ILC2 cells, initiate an inflammatory response that includes recruitment and activation by cytokines of immune effector cells, with eosinophils contributing to bronchoconstriction, microvascular permeability, and airway remodeling (Kumar et al., 2005; Locksley, 2010).

The lung is densely innervated by sensory fibers, most of which express markers of nociceptors, including the transient receptor potential (TRP) channels TRPV1 and TRPA1 (Ni et al., 2006). Airway nociceptors respond to chemical, mechanical, or thermal stimuli to initiate essential protective airway reflexes, such as coughing (Canning et al., 2006). Asthmatic patients have a denser network of these fibers around small airways (Barnes, 1996; Myers et al., 2002) and a reduced activation threshold in response to airborne irritants (Canning and Spina, 2009). Patients also display elevated neuropeptide levels in bronchoalveolar lavage fluids (BALFs) (Lilly et al., 1995). These features indicate changes in and excess activity of peptidergic sensory fibers (Patterson et al., 2007). The large-pore cation channels TRPV1 and TRPA1 are activated by exogenous chemical irritants, such as cigarette smoke (Kanekzaki et al., 2012), and also directly and indirectly via GPCR- and receptor tyrosine kinase coupling by many endogenous ligands generated during inflammation, including protons, lipids, endogenous cannabinoids, bradykinin, and NGF (Szallas et al., 2007). Stimulation of nociceptor peripheral terminals results in calcium-mediated vesicular release of neuropeptides, like substance P and calcitonin gene-related peptide (CGRP), to generate neurogenic inflammation, which is characterized by increased vascular permeability and vasoconstriction. This is amplified and spreads by the antidromic reflex, where the sensory input in one branch of a sensory neuron initiates an action potential back down a
connecting branch to its peripheral terminal (Chiu et al., 2012). Nociceptors may contribute to airway disease both by their capacity to produce bronchoconstriction (Tränkner et al., 2014) and local neurogenic inflammation (Caceres et al., 2009; Hox et al., 2013). Supporting involvement of sensory fibers in key aspects of type 2 inflammation, genetic knockout (KO), or pharmacological antagonism of the TRPA1 channel reduced inflammation in a mouse model of allergic airway disease (Caceres et al., 2009), while ablation of TRPV1 afferents blocked bronchial hyperresponsiveness (Tränkner et al., 2014). However, exactly how sensory neurons and immune cells cooperate to amplify immunopathology and direct various types of inflammation is unknown (Chiu et al., 2013; Liu et al., 2014; Nussbaum et al., 2013; Riol-Blanco et al., 2014; Wilson et al., 2013).

We have investigated the contribution of lung nociceptor neurons to the generation and resolution of allergic airway inflammation by asking if global ablation of all nociceptor neurons is required for the generation and resolution of allergic airway inflammation resolution. We found that sensory neurons, in part through the vasoactive intestinal peptide (VIP)-VPAC2 axis, drive CD4+ and ILC2 cell production of cytokines including IL-5, and reciprocally that IL-5 activates sensory neurons. Our results indicate that nociceptors play a major role in amplifying adaptive immune responses in the lung, and they show that local pharmacological silencing of nociceptors interrupts the pro-inflammatory signaling loop between neurons and immune cells to enhance allergic airway inflammation resolution.

RESULTS

Nociceptor Activation and Allergic Airway Inflammation

Allergic inflammation and bronchial hyperresponsiveness can be induced in mice by an initial sensitization to an allergen, in this case ovalbumin (OVA) (intraperitoneally [i.p.], days 0 and 7), followed by inhaled OVA challenges (days 14–17) (Figure 1A). To investigate if sensory fibers play a role in allergic airway inflammation, we first performed lung nociceptor gain-of-function experiments in vivo. Mice were treated with intranasal instilled capsaicin, a selective TRPV1 agonist (Szallasi et al., 2007), and 24 hr later BALF was immunophenotyped. In naive mice (no OVA exposure), capsaicin treatment increased CD45+ cells (marker of all immune cells) (Figure 1B). In OVA-treated mice, capsaicin administration on day 18 (the day after completing OVA challenges and time of maximal inflammation) further increased the already elevated levels of CD45+ cells (Figure 1B). These included eosinophils (Figure 1C), macrophages (Figure 1D), and lymphocytes (Figure 1E). The pro-inflammatory effect of capsaicin also was observed in lungs of lymphocyte reporter mice (LCKCre+ eGFPm; Figures 1F and 1G). We conclude that exogenous activation of lung nociceptors increases airway leukocytes. The larger effect in OVA-challenged mice than naive mice implies that factors released by nociceptors in inflamed lung augment immune cell recruitment.

Nociceptor Ablation and Allergic Airway Inflammation

We next used targeted diphtheria toxin-based cell ablation (Palmite et al., 1987) to explore if nociceptor neurons are required for lung inflammation in the OVA mouse model. NaV1.8 is a TTX-resistant voltage-gated sodium channel expressed by nociceptors, including those in the nodose ganglion (Muroi and Undem, 2014) and the majority of nodose ganglion lung afferents (Kwong et al., 2008). NaV1.8-Cre++ DTA++ mice are devoid of all NaV1.8-expressing nociceptors (Stirling et al., 2005) and have no response to noxious heat, mechanical stimuli, or capsaicin (Chiu et al., 2013). In WT mice and NaV1.8-Cre++ DTA-- littermate control mice (with intact nociceptors), numbers of CD45+ cells, including eosinophils and lymphocytes, increased substantially in BALFs obtained on protocol day 21 (4 days after the last inhaled OVA challenge) (Figures 2A–2D). In contrast, OVA-exposed NaV1.8-Cre++ DTA++ mice (with ablated nociceptors) showed significantly dampened immune cell infiltration on day 21, with fewer eosinophils, macrophages, and lymphocytes (Figures 2A–2D).

Silencing Airway Nociceptors in Non-inflamed Lungs

Since ablating nociceptors during development might conceivably cause compensatory changes in the lung and immune system, we shifted to a strategy to temporarily silence afferents in the adult lung using large-pore ion channels as a drug entry port for charged sodium channel blockers to produce targeted action potential blockade (Binshtok et al., 2007; Brenneis et al., 2013). We first assessed the efficiency of sensory neuron silencing using QX-314, a permanently charged quaternary derivative of lidocaine, in reversing neuropeptide release from nociceptors and consequent vascular leakage in the lung. Activating lung nociceptors in naive mice with capsaicin (1 μmol, 20 μl instilled intranasally) induced significant increases in CGRP levels in BALFs collected 60 min later (Figures 3A–3D). Pre-treatment with QX-314 (100 μM) by inhaled nebulizer 1 hr prior to the capsaicin (when no large-pore channels were activated) failed to alter subsequent capsaicin-induced increases in the neuropeptide, showing that, when administered by itself in the non-inflamed lung, QX-314 fails to block nociceptors, an expected result since there is no portal for entry into nociceptors and it is ineffective when administered extracellulary (Binshtok et al., 2007; Figure 3A). However, when administered just after capsaicin administration, which opens TRPV1 channels, QX-314 blocked CGRP release into BALF (Figure 3B). Co-administration of QX-314 with capsaicin also blocked development of plasma extravasation in the lung, a measure of capillary permeability due to neuropeptide release (Figure 3C). These data show that, when large-pore channels are exogenously activated by TRP
channel agonists, QX-314 can enter into lung nociceptors and inhibit them.

**Silencing Airway Nociceptors in Inflamed Lungs**

Reduced OVA-induced allergic airway inflammation in TRPA1-KO mice (Caceres et al., 2009) and following TRPV1-small interfering RNA (siRNA) knockdown (Mabalirajan et al., 2013; Rehman et al., 2013) indicates activation of these channels by endogenous ligands during allergic inflammation, providing the opportunity to target QX-314 into nociceptors in inflamed lungs without the need for administration of an exogenous TRP channel agonist. When QX-314 was administered 60 min prior to a capsaicin challenge to OVA-challenged mice on day 18, at the height of inflammation, capsaicin-evoked neuropeptide release was, unlike the situation in naive mice, markedly decreased (Figure 3D), showing that QX-314 treatment by itself in OVA-exposed mice locally blocked nociceptors. To further assess afferent silencing, intranasal capsaicin (500 nmol) was instilled
in OVA-challenged mice, and nodose ganglion neuron activation was measured by phospho-ERK (p-ERK) immuno-labeling. When OVA-challenged mice were pre-exposed to QX-314 (100 μM) 1 day prior to p-ERK measurements, fewer lung afferent neurons, identified by retrograde Dil-label (Figure S1), were p-ERK positive than in vehicle-treated mice (18.5% versus 86.5% [Figures S1A–S1D]), demonstrating that inhaled QX-314 silences lung nociceptors in OVA-treated mice. Activation of lung nociceptor TRP channels, either by capsaicin in naive animals or by endogenous ligands during allergic inflammation, permits sufficient QX-314 entry to block local nociceptor activity (Figures S1E–S1G).

Nociceptor Silencing and Allergic Airway Inflammation

Single 100-μM treatment with QX-314 on day 18, after OVA inhalation challenges on days 14–17 in OVA-sensitized mice, substantially reduced the immune cell infiltration normally seen on day 21, with decreased BALF CD45⁺ cells (total immune cells) and decreased eosinophils, macrophages, and lymphocytes (Figures 4A–4D). Similar results were seen in H&E-stained lung tissue (Figures 4E–4G). The QX-314 effects were independent of sex, age (8 versus 16 weeks), and strain (C57Bl/6 versus BALB/c) (data not shown). In addition, this treatment decreased by 1.75-fold the airway basement membrane thickening (Figure 4H). We also tested if sensory neuron silencing reversed type 2 inflammation in the clinically relevant HDM model (Johnson et al., 2004). Briefly, 8-week-old male BALB/c mice were sensitized with HDM (days 1–5) and challenged on days 8–10. On day 15, HDM-challenged mice showed increased BALF CD45⁺ cells (Figure 4I) and lymphocytes (Figure 4J), both of which were reduced by QX-314 (100 μM, day 12) treatment. To establish if this was general to all types of allergic inflammation, we analyzed the impact of silencing in a type 1-skewed allergic airway inflammation model. Here, instead of sensitizing mice with aluminum hydroxide and OVA, as in all the experiments above, which produces a Th2-skewed inflammation (Bogaert et al., 2011), mice were sensitized with a mixture of complete Freund’s adjuvant (CFA) and OVA (Bogaert et al., 2011), which models non-eosinophilic Th1-skewed asthma. These mice had a ~2-fold increase in the Th1/Th2 ratio (defined as CD4⁺IFNγ⁺/CD4⁺IL4⁺ cells) compared to AlOH/OVA-sensitized mice (Figure 4K). QX-314 failed to impact levels of CD45⁺ cells (Figure 4L), eosinophils, macrophages, and lymphocytes on day 21 in this model (data not shown). Sensory neuron effects on inflammation are context dependent and contribute to type 2 models of allergic airway inflammation, but not a type 1 model.

Inhaled lidocaine, a short-acting sodium channel blocker, has anti-inflammatory effects on murine asthma models (Serra et al., 2012) and in patients (Weiss and Patwardhan, 1977), but directly suppresses immune cells (Serra et al., 2012). We therefore investigated if QX-314 has direct effects on immune cells. QX-314 had no impact on in vitro survival, chemotaxis, and activation of lung macrophages and eosinophils (data not shown), and exposure to QX-314 (up to 1 mM) had no effect on Th0, Th1, and Th2 cell proliferation or cytokine production in vitro (data not shown). We conclude that the immune-suppressing actions of QX-314 are due to nociceptor silencing. The anti-inflammatory effect of nociceptor silencing with QX-314 was replicated with a chemically distinct sodium channel blocker, a permanently charged derivative of mexiletine, N-methyl-mexiletine (NMM). When NMM was administered by nebulizer (on day 18) to OVA-treated mice, BALF-harvested immune cell counts were significantly reduced (Figure S2), albeit with less potency than QX-314. The same dose of uncharged mexiletine failed to resolve the OVA-mediated allergic airway inflammation (Figure S2). Thus, the ability of charged compounds to penetrate into nociceptors through activated large-pore ion channels enables the blockade of sodium channels for longer periods, and this is critical to how silencing sensory neurons reduces inflammation.

We next examined the effect of sensory neuron silencing on bronchial hyperresponsiveness. Both genetic ablation of lung afferent neurons (data not shown) and QX-314 silencing on day 18 reversed OVA-mediated bronchial hyperresponsiveness, as measured on day 21 by ED200RL (Figure 4M), lung elastance (Figure 4N), and resistance (Figure 4O). Specifically, the dose of methacholine (MCh) required to produce a 200% increase in RL (i.e., log ED200RL) decreased significantly (p < 0.001) from 6.38 ± 0.74 in control mice to 0.79 ± 0.06 after OVA challenge, while QX-314 increased by ~3-fold the log ED200RL values in OVA-challenged mice (Figure 4M). NMM also reduced airway hyperresponsiveness (data not shown).
To functionally explore the consequences of airway hyperresponsiveness in mice, we measured daily voluntary wheel running. Individual animals were followed over the course of the allergen protocol (Figure 1A) and their daily level of voluntary exercise (1 hr, dark, 21:00–1:00 hr) was analyzed. At the peak of inflammation (day 18), mice showed a significant decrease in travel distance ~25% compared to their pre-challenge period (day 13) (Figure 4P), and this was matched by an equivalent decrease in exercise duration. Voluntary wheel running distance was rescued by QX-314 treatment, measured 24 hr later (Figure 4P). Local silencing of lung nociceptors by a single exposure to a charged sodium channel blocker at the peak of allergen-induced inflammation reduced two cardinal features of allergic asthma: immune infiltration and bronchial hyperresponsiveness.

**IL-5 Activates Lung Nociceptors**

Our data suggest that nociceptors are activated during exposure to allergens in sensitized animals, but the mechanisms responsible are unknown. Skin nociceptors are activated by the cytokine IL-1β (Blinthok et al., 2008), and we hypothesized that similar signaling could occur during allergic airway inflammation. To look for candidates, we asked if silencing lung nociceptors with QX-314 reduced BALF levels of cytokines, and we discovered decreased IL-5 (Figure 5A), eotaxin-2, IL-4, IL-9, IL-10, IL-13, IP-10, MCP-1, TNF-α, and TARC (Table S1). Transcript profiling of the naive nodose ganglion revealed that lung Na1.8+ nociceptors express receptors for some of these cytokines, including IL-33R, INF-γR, and RANTES (Table S1). Transcript profiling of the naive nodose ganglion revealed that lung Na1.8+ nociceptors express receptors for some of these cytokines, including IL-33R, INF-γR, and RANTES (Table S1). Transcript profiling of the naive nodose ganglion revealed that lung Na1.8+ nociceptors express receptors for some of these cytokines, including IL-33R, INF-γR, and RANTES (Table S1). Transcript profiling of the naive nodose ganglion revealed that lung Na1.8+ nociceptors express receptors for some of these cytokines, including IL-33R, INF-γR, and RANTES (Table S1).

Removing extracellular calcium eliminated the IL-5 signal (Figure 4G), suggesting flux through membrane-bound channels. Whole-cell patch clamp recordings in current-clamp mode from small cells (capacitance <45 pF) that had responded to IL-5 by calcium imaging showed that IL-5 perfusion (1 μg/ml) depolarized the cells by ~6 mV (Figures 5H and 5I; n = 12 cells), an effect that was reversible after extensive washout (more than 20 min). Before IL-5 perfusion, cells had a stable resting membrane potential (RMP) with no spontaneous action potential firing; however, occasional spontaneous spiking was observed following IL-5 treatment (2/12 patched cells). The current needed to trigger an action potential (rheobase) was smaller when IL-5 was present (Figures 5J and 5K; n = 7 cells), but no difference in spiking frequency during a ramp current was observed (data not shown). We conclude that nociceptors can be directly activated by IL-5.
Lung Nociceptors Activate ILC2 and Lymphocytes

Lung epithelial and dendritic cells are activated upon an allergen challenge to stimulate resident lung ILC2 cells (Licona-Limón et al., 2013). ILC2 cells are implicated in the onset of asthma, and they are directly activated by IL-25 and IL-33 released from goblet and dendritic cells to act upstream of Th2 cells, B cells, eosinophils, smooth muscle cells, and macrophages. ILC2 cells produce IL-5, IL-9, and IL-13 and are resident in the airways, where they orchestrate type 2 immunity (Barnig et al., 2013; Licona-Limón et al., 2013). Activation of ILC2 cells typically

Figure 4. Airway Sensory Neuron Silencing Reduces Lung Inflammation and Hyperresponsiveness

(A–D) OVA-exposed mice develop increased CD45+ immune cell counts in BALF (A), which include eosinophils (B) and lymphocytes (D), but not macrophages (C). (E and F) Silencing lung sensory neurons with QX-314 (100 μM, 72 hr prior to measurement; blue squares) decreased these immune cell responses (A–H). Representative H&E-stained sections of OVA-exposed lungs treated with saline (E) or QX-314 (100 μM; F) are shown. Scale, 100 μm.

(G and H) Immune cell infiltration severity (G) and basement membrane thickening (H) measured by tissue morphometry in HE sections are shown.

(I and J) HDM challenge increased BALF CD45+ cell counts, an effect reversed by QX-314 (100 μM).

(K and L) CFA/OVA sensitization produced a greater increase in Th1/Th2 cell ratio than AlOH/OVA sensitization (K). QX-314 (100 μM) reduced BALF CD45+ cell counts in the AlOH/OVA-, but not the CFA/OVA-sensitized model (L). Mean ± SEM; two-tailed unpaired Student’s t test (n = 4–25 animals/group, four cohorts).

(M–P) Change in airway reactivity measured as ED200RL (M), resistance (N), and elastance (O) in OVA-exposed mice treated with QX-314 (D–F; 100 μM, day 18) or saline; difference in vehicle- (%) and OVA-exposed (%), p < 0.001. OVA-exposed mice performed less voluntary wheel running (P) (1-hr assessment) than control mice, an effect reversed by QX-314 (100 μM, day 18) assessed 24 hr after silencing. Two-tailed unpaired Student’s t test (n = 4–40 animals/group, two to three cohorts).
precedes that of Th2 cells, although transactivation and cooperation occur (Halim et al., 2014; Licona-Limon et al., 2013). Typically activated ILC2 cells produce IL-13 and have higher levels of the IL-33R, ST2, while a subset of Th2 cells produces IL-5 and IL-13, the predominant effector cytokines in asthma. We therefore set out to assess if nociceptor ablation had any effect on ILC2 cell or CD4+ cell activation, as measured by surface markers and cytokine production. To do this, we examined early immune changes after two OVA challenges on day 16. Relative to littermate controls (Na V1.8-Cre+/C0/DTA+/C0), OVA-exposed mice with ablated nociceptors (Na V1.8-Cre+/C0/DTA+/C0) showed decreased BALF levels of CD45+, as seen previously (Figures 2A and 6A). In addition, there were fewer CD4+ (Figure 6B) and ILC2 (Figure 6C) cells. Moreover, nociceptor-ablated mice demonstrated decreased numbers of IL-13+ ILC2 (Figure 6D) and lower expression of CD25 (Figure 6E) and ST2 (Figure 6F), ILC2 activation markers (Wilhelm et al., 2011). Similarly, QX-314 administration at the peak of inflammation (100 μM, day 18) reduced the rise in total CD4+, CD4+IL-5+, and CD4+IL-13+ cells (BALF, on day 21). Thus, both genetic ablation and pharmacologic silencing of nociceptors result in decreased activation of ILC2s and Th2 effector cytokine production.

Lung Nociceptors Release VIP

The effect of sensory neurons on ILC2 and CD4+ cells likely involves multiple pathways and several candidate neuropeptides could be involved. Genomic analysis of lung-resident ILC2 cells has revealed expression of receptors for several neuropeptides released by sensory neurons, including SP, CGRP, and VIP (Saenz et al., 2013), providing an opportunity for nociceptors to directly communicate with these cells. We chose to examine VIP, both because it is present at high levels in nodose ganglion neurons.
neurons (Figure 7A) and because its two G protein-coupled receptors VPAC1 and VPAC2 are expressed by and exert a powerful regulatory effect on T cells, including differentiation, migration, and cytokine production (Delgado et al., 2000). We found that Na_v1.8+ nodose ganglion neurons express VIP (Figure 7B), including lung afferents in OVA-exposed mice (DiI retrogradely labeled) (Figure S3A). Cultured nodose ganglion neurons stimulated with capsaicin (Figure S3B) or IL-5 (Figure 7C) released VIP, while BALF from OVA-exposed mice contained elevated VIP compared to vehicle-challenged mice and this...
Figure 7. IL-5 Provokes Sensory Neuron Release of VIP to Activate ILC2 and Recruit CD4+ Cells
(A) Gene profiling of naive Na\(_{v}1.8^+\) nodose ganglion neurons reveals expression of nociceptor markers and VIP.
(B) A VIP reporter mouse (VIP-Cre\(^{-}\)/EGFP/Gfp-tomato\(^{+/}\)/green) reveals that ~80% of Na\(_{v}1.8^+\) (magenta) nodose ganglion neurons express VIP (green) (scale bar, 50 \(\mu\)m).
(C) IL-5 (1 hr, 3 \(\mu\)g/ml) induced VIP release from nodose ganglion neurons from OVA-exposed mice.
(D) These mice have elevated BALF VIP levels on day 21 compared to vehicle-exposed mice (white bar), which is decreased by QX-314 treatment (100 \(\mu\)M, day 18; blue bar).
(E and F) In OVA-exposed lungs, the VPAC2 antagonist PG 99465 (100 nM, every 12 hr starting on day 16; pink squares) did not impact resident ILC2 numbers (E) but reduced ILC2 activation IL-13\(^+\) cells (F).
(G and H) The VPAC2 agonist BAY 55-9837 (10 nM, every 12 hr for 96 hr; red squares) increased and the VPAC2 antagonist PG 99465 (100 nM, every 12 hr for 96 hr; pink squares) decreased CD4\(^+\) cell numbers (G) and IL-5 mRNA expression in FACS-sorted CD4\(^+\) cells (H). Mean ± SEM; two-tailed unpaired Student’s t test (\(n = 3–14\) animals/group, one to two cohorts).
was reduced by inhaled QX-314 (Figure 7D). Nodose ganglia from OVA-exposed mice expressed more VIP transcripts than naive mice (data not shown). These data indicate that VIP is released in the inflamed lung and this can be blocked by silencing neurons with a charged sodium channel blocker.

**VIP Acts on ILC2 and Th2 Cells**

We next asked if VIP can act on ILC2 and T cells. We isolated CD4\(^+\) T-cells from spleens and lymph nodes of naive mice, and we differentiated them in vitro under Th1-, Th2-, and Th17-skewing conditions, followed by exposure to VIP. When CD4\(^+\) T-cells cultured under Th2-skewing conditions were exposed to recombinant mouse VIP (500 nM), their transcript levels of IL-13 (data not shown) and IL-5 (Figure S3C) increased, suggesting that VIP contributes to the competence of Th2 cells to transcribe these type 2 regulatory cytokines. VIP (0–1.0 \(\mu M\)) did not affect transcription of IL-5 or IL-13 in T cells cultured under Th0-, Th1-, and Th17-skewing conditions (data not shown). The VPAC2 antagonist PG 99465 administered early in the OVA challenge (100 nM in 50 \(\mu l\), intranasally, every 12 for 48 h starting on day 14) significantly decreased CD4\(^+\) cells in the whole lung on day 16, particularly those producing IL-13 (Figures S3D and S3E). Resident lung ILC2 numbers were not affected by VPAC2 blockade (Figure 7E), but their activation was significantly reduced, as indicated by decreased IL-13 intracellular staining (Figure 7F) and decreased surface expression of ST2 (Figure S3G). Impaired ILC2 activation may be important given the key role for this population in the initiation of allergic airway inflammation (Hailm et al., 2014). When the VPAC2 antagonist was given for a longer period, over the full duration of OVA challenge (twice daily on days 14–18), it reduced BALF total immune cell number or activation (data not shown). Activation of VPAC2 in OVA-exposed mice with a selective agonist further increased CD4\(^+\) cell numbers (Figures 7G, S3H, and S3I) and IL-5 mRNA levels (Figure 7H). VIP signaling through VPAC2 may play, therefore, a significant role in the activation of ILC2 cells and cytokine expression by CD4\(^+\) T-cells, and may account, at least partially, for the ability of nociceptors to amplify type 2 inflammation in the lung.

**DISCUSSION**

The nervous and immune systems work in concert to protect against environmental dangers and also can fail together in disease states, including asthma. Nociceptor-immune interactions appear to contribute to arthritis-induced inflammation (Levine et al., 1984), colitis (Engel et al., 2011), psoriasis (Riol-Blanco et al., 2014), and acute lung injury (Su et al., 2005); however, the mechanisms by which this happens remain uncertain. Here we have demonstrated a complex interplay between nociceptors and immune cells. Through pharmacological silencing and genetic ablation of nociceptors in the OVA- and HDM-induced mouse models of airway inflammation, we have uncovered a major upstream contribution of these fibers to the generation and persistence of type 2 allergic airway inflammation and bronchial hyperresponsiveness. Whereas direct stimulation of lung nociceptors by capsaicin promotes neuropeptide release and immune cell infiltration, silencing sensory neurons or ablation of Na\(_{v}1.8\) nociceptors substantially reduces immune cell infiltration and bronchial hyperresponsiveness. We also have identified a means of communication between sensory neurons and the select set of immune cells pivotal for the initiation and amplification of type 2 allergic inflammation. We found that IL-5, a type 2 effector cytokine produced by multiple immune cells, directly activates sensory neurons leading to secretion of the neuropeptide VIP, and that VIP acts on ILC2 and CD4\(^+\) cells to induce cytokine production. In addition, we discovered that charged sodium channel blockers, which specifically and locally silence TRP-activated sensory neurons, interrupt this signaling loop and reduce well-established inflammatory responses.

Several studies have suggested that nociceptors play a role in adaptive immune responses. A reduction in allergic airway inflammation was shown in TRPA1-KO mice (Caceres et al., 2009) and upon TRPV1-siRNA knockdown (Mabalirajan et al., 2013; Rehman et al., 2013), while C-fiber denervation in rats (produced by neonatal high-dose capsaicin exposure) decreased OX-6\(^+\) dendritic cell numbers in the lung; pulmonary lymphoid infiltration after allergen challenge (hen egg lysozyme) (Kradin et al., 1997); and PAR2-mediated airway constriction, pulmonary inflammation, and edema (Su et al., 2005). Collectively, these findings, together with studies on atopic dermatitis and psoriasis (Riol-Blanco et al., 2014; Wilson et al., 2013), indicate that nociceptors can potentiate adaptive immune responses; however, the mechanisms responsible were not identified in these studies. Here we show that nociceptors are crucial to the generation and persistence of type 2 airway inflammation, identify a pharmacological approach for using this insight therapeutically, and identify some specific mechanisms for these neuro-immune interactions.

Allergic airway hyperresponsiveness may result both from local signaling by immune cells directly to airway smooth muscle cells and through nociceptor-mediated stimulation of subepithelial parasympathetic efferents through central and local reflexes. A recent study found that ablation of a subset of TRPV1\(^+\) sensory neurons reduced bronchial hyperresponsiveness (Tränkner et al., 2014). We replicated this finding using Na\(_{v}1.8\) ablation, and we extended it by showing similar effects with the pharmacological silencing of pain fibers, including on daily voluntary exercise, a new functional readout of airway hyperresponsiveness. Tränkner et al. reported that ablation of TRPV1 sensory neurons did not reverse airway inflammation, in contrast to our pharmacological and genetic ablation data that revealed such an effect. Explanations for this discrepancy include different allergy models (intranasal allergen versus nebulization), timing of measurements (24 versus 96 h), assessment methods (Wright-Giemsa stain versus FACS immunophenotyping), and, most importantly, different targeted neuron populations (TRPV1 versus Na\(_{v}1.8\)). Na\(_{v}1.8\) is expressed by 80% of nociceptors (Muroi and Undem, 2014) and the majority of nodose ganglion lung afferents (Kwong et al., 2008), while TRPV1 is expressed by only 50% of Na\(_{v}1.8\) nociceptors. This
suggests that a broad population of nociceptors needs to be silenced or ablated to interrupt their pro-inflammatory actions.

Th2 and ILC2 cells are both critical to the pathogenesis of allergic airways disease. We found that after an allergen challenge in Th2-skewed-sensitized mice, sensory neurons stimulate cytokine production in CD4+ and ILC2 cells. ILC2 cells are implicated in the onset of asthma and are directly activated by IL-25 and IL-33 released from goblet and dendritic cells, and they act upstream of Th2 cells, B cells, eosinophils, smooth muscle cells, and macrophages (Walker et al., 2013). Therefore, activation of sensory neurons on allergen exposure may be a very early event in igniting inflammation in a sensitized animal. We asked how sensory neurons may communicate with Th2 and ILC2 cells to potentiate/initiate inflammation. Activation of nociceptors, through calcium influx, induces the release of neuropeptide transmitters from vesicles in the peripheral terminals. In the lung, release of these neuropeptides occurs in response to chemical agents (capsaicin, citric acid, nicotine, cigarette smoke, histamine, and bradykinin) and physical factors (mechanical probing, dry gas, and hypertonic aerosols) (Bessac and Jordt, 2008). Classically, such neuropeptide release (with a focus on substance P and CGRP) was thought to trigger only local increased capillary permeability and vasodilation; but, there have been suggestions that nociceptor-mediated peptide release may contribute to inflammation in arthritis (Levine et al., 1984), colitis (Engel et al., 2011), psoriasis (Riol-Blanco et al., 2014), and acute lung injury (Su et al., 2005). Lung-resident ILC2 cells express receptors for the sensory neuron neuropeptide SP, CGRP, and VIP (Saenz et al., 2013). Established neuropeptide-mediated immune cell regulation includes the CGRP and VIP biasing of dendritic cells toward the Th2/Th1 response; enhanced dendritic cell migration to the lymph node (Ding et al., 2008); and activation of mast (Ansel et al., 1993), Langerhans (Hosoi et al., 1993), Th2 cells (Delgado et al., 2000; Ding et al., 2008), and ILC2 cells (Nussbaum et al., 2013).

Our data suggest that release of VIP by sensory fibers in the lung activates ILC2 and CD4+ T cells, in addition to their canonical activation by cytokines, and that this contribution is sufficiently large that silencing sensory neurons substantially reduces and increases resolution of allergic inflammation (Figure 8). The action of VIP on immune cells is context and cell type dependent. Unstimulated Th cells have high basal expression of VPAC1 (Harmar et al., 1998). T cell antigen receptor stimulation, however, upregulates VPAC2 and diminishes VPAC1 expression, and, in consequence, VPAC2 is the dominant transducer of VIP’s effects on Th2 cells (Lara-Marquez et al., 2001). This shift from VPAC1 to VPAC2 in activated T cells shifts the balance from the delayed-type cellular-protective hypersensitivity responses mediated by Th1 cells to the immediate-type allergic immune responses mediated by Th2 cells. Supporting a role for VPAC2 signaling in type 2 immune responses, transgenic mice with high constitutive VPAC2 expression in T cells show blood eosinophilia, elevated serum IgE levels, greater IgE antibody responses, and cutaneous immediate-type reactions to allergy-producing antigens (Voice et al., 2001), while VPAC2-KO mice show Th1-associated responses (Goetzl et al., 2001). Nociceptor

Figure 8. Model of Nociceptor Involvement in Type 2 Inflammation

During allergen exposure, lung afferents are activated by dendritic and epithelial cells. Dendritic cells also polarize precursor Th cells into Th2 cells. Activated nociceptors release VIP, which stimulates lung-resident ILC2 and newly differentiated Th2 cells via the VPAC2 receptor. Type 2 cytokines, including IL-5 and IL-13, are released by ILC2 and Th2 cells and initiate the chemotaxis and activation of eosinophils and macrophages. IgE secretion by B cells, mucus production by goblet cells, and smooth muscle contraction, culminating in allergic inflammation and bronchial hyperresponsiveness. IL-5 activates nociceptors to trigger VIP and other neuropeptide release, leading to additional IL-5 production. Scheme inspired by Licona-Limón et al. (2013) and Vercelli (2008).
directly activate a subset of TRPA1 + sensory neurons (as well from keratinocytes in a mouse model of atopic dermatitis to mechanisms to activate sensory neurons during such inflammation ( Figure 8 ).

There may well be additional IL-5, nociceptors, VIP, ILC2, and Th2 cells, that amplifies hyperreactivity ( Shi et al., 1998 ).

tor of eosinophil cationic protein (ECP) and transforming growth factor β (TGF-β) to induce airway smooth muscle inflammation and hyperreactivity (Shi et al., 1998).

We have uncovered a positive feedforward loop, involving IL-5, nociceptors, VIP, ILC2, and Th2 cells, that amplifies type 2 inflammation ( Figure 8 ). There may well be additional mechanisms to activate sensory neurons during such inflammation, for example, thymic stromal lymphopoeitin (TSLP), which is implicated in asthma (Gauvreau et al., 2014). TSLP is released from keratinocytes in a mouse model of atopic dermatitis to directly activate a subset of TRPA1 + sensory neurons (as well as immune cells) to trigger itch (Wilson et al., 2013). Furthermore, in psoriasis-like conditions, skin allergen-sensitized dendritic cells make direct contact with afferent sensory neurons and activate them (Rioli-Blanco et al., 2014), although the mediator responsible is not yet identified.

Currently, there is no treatment that accelerates the resolution of inflammation in asthma (Levy et al., 2012). Several drugs control disease symptoms and help abort attacks (Fanta, 2009). Bronchodilators, β2-agonists, or anti-cholinergics give immediate relief through relaxation of smooth airway muscle (Green et al., 2003). Immune modulators inhibit inflammation, with corticosteroids the primary treatment modality (Green et al., 2003); however, chronic steroid use leads to adverse effects (Locksley, 2010). Despite the effectiveness of current therapy for mild asthma, patients with severe asthma have frequent exacerbations and excess morbidity. Asthma is a heterogeneous condition, but a therapeutic approach that targets nociceptors upstream of type 2 inflammation might provide a broadly effective treatment for many patients (Barnes, 2004). Nevertheless, sensory neuron interaction with immune cells appears to be highly cell and context dependent; for example, during pathogen invasion, the release of neuropeptides (CGRP, galanin, and somatostatin) suppresses innate immune responses (Chiu et al., 2013), in contrast to the amplifying role we report here for type 2 allergic airway inflammation, and treatment would need to be evaluated and individualized accordingly.

In conclusion, the silencing and genetic ablation of nociceptors has uncovered a major upstream contribution of these fibers in the generation and persistence of type 2 allergic airway inflammation and bronchial hyperresponsiveness. Sensory neurons, upon activation by allergen exposure in sensitized animals, control through local neuropeptide release at their peripheral terminals type 2 inflammation, acting on ILC2 and CD4 + cells. These cells secrete cytokines such as IL-5 that recruit effector immune cells integral to the disease state, and also further activate sensory neurons. Silencing sensory neurons provides, therefore, a potential strategy worth exploring for the treatment of type 2 allergies, potentially including conjunctivitis, rhinitis, and asthma. This strategy is highly specific, only targeting neurons whose TRP channels are activated by inflammation, with expected low systemic side effects (positively charged drugs have limited capability of spreading) and a long duration of action (positively charged compounds should remain trapped inside neurons for prolonged periods), constituting a novel therapeutic approach to allergic airway inflammation centered on interrupting sensory neuron immune signaling.

**EXPERIMENTAL PROCEDURES**

All procedures were approved by the Institutional Animal Care and Use Committees of Boston Children’s Hospital. Allergic airway inflammation was studied in an OVA-based model (Haworth et al., 2008). On days 0 and 7, mice were sensitized by 200-μl i.p. injections of a solution containing 1 mg/ml OVA (Sigma-Aldrich) and 5 mg/ml aluminum hydroxide (Sigma-Aldrich). On days 14–17 (10:00 am), mice were exposed to 6% OVA aerosol for 25 min. OX-314 (100 μM) was nebulized on day 18, mice were sacrificed on day 21, and BALF was harvested; cells were isolated, counted, and immunophenotyped using FACS.

**Statistics**

Data are expressed as mean ± SEM from 4–36 mice. Statistical significance determined by two-tailed (unpaired or paired [patch-clamp]) Student’s t test; p values less than 0.05 were considered significant. Numbers of animals are defined in figure legends.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.neuron.2015.06.007.

**AUTHOR CONTRIBUTIONS**


**ACKNOWLEDGMENTS**

This work was supported by the Hood Foundation (C.J.W.) and NIH grants PO1NS072040 (C.J.W. and B.P.B.); R37NS039518 (C.J.W.); and R01-HL122531, AI088084, and P01-GM095467 (B.D.L.). S.T., R.-E.E.A., P.R.B.,...
REFERENCES


